Pmda - Pharmaceuticals and Medical Devices Agency
Menu
Close

Events and Symposia

PMDA-ATC Pharmaceuticals Review Webinar 2020 for NPRA, Malaysia

 

About this event

The Pharmaceuticals and Medical Devices Agency (PMDA) is pleased to announce that PMDA will hold the “PMDA-ATC Pharmaceuticals Review Webinar 2020 for NPRA, Malaysia”. The webinar will cover topics relating to the regulation and review process of pharmaceuticals, specially focusing on the First in Human (FIH) trials and Good Clinical Practice (GCP) inspection, and aims to provide an opportunity for the participants to deepen the knowledge of the regulatory systems by sharing experiences between Malaysia and Japan.    
 
The webinar is offered by the Asia Training Center for Pharmaceuticals and Medical Devices Regulatory Affairs (PMDA-ATC) in collaboration with the National Pharmaceutical Regulatory Agency (NPRA) and will be held online using the Cisco Webex teleconferencing systems. The webinar is for regulators working for NPRA or other personnel approved by NPRA, but not open to those from other countries/regions nor industry. The training will be provided in English (with consecutive translation in some sessions).

Who should attend

Regulators of NPRA who are currently engaged in the review of pharmaceuticals or the personnel of other organizations, who is working closely with NPRA within the theme of this webinar;

  • Basic knowledge of the regulations of pharmaceuticals review is required.
  • All participants are required to actively participate in all of the sessions.

Date / Time

  • November 6, 2020 10:00 – 13:00 JST (9:00-12:00 MYT)

Program

See attached the program

Contact us

Attention: Registration will be managed by NPRA.
 
Secretariat, PMDA Asia Training Center
E-mail: PMDA-ATC●pmda.go.jp
Division of Training Center Management
Office of International Programs
Pharmaceuticals and Medical Devices Agency
Shin-Kasumigaseki Building, 3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013, Japan
 
(Note: For the purpose of security, @ in the e-mail addresses are replaced with ●. Please replace ● with @ when you send an e-mail.)